帯状疱疹とその予防に関する考察
わが国では帯状疱疹は年間4.15 人/1,000 人で，50 歳以上での発症率は，5.23～7.84 人/1,000 人であり，80歳までに，3 人に1 人が経験するありふれた感染症である．本稿では，水痘と帯状疱疹の関係，水痘ワクチンによる帯状疱疹予防の意義，水痘ワクチンによる60 歳以上の成人での帯状疱疹および帯状疱疹後神経痛予防の大規模臨床試験について考察した．また，帯状疱疹の予防という観点の研究は1980 年代から行われてきた．そして，水痘患者との接触や水痘ワクチンの接種は，既感染者の水痘帯状疱疹ウイルスに対する免疫を賦活化できることが報告されてきた．これらの一連の研究に続いて，2005...
Saved in:
| Published in | 感染症学雑誌 Vol. 84; no. 6; pp. 964 - 701 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | Japanese |
| Published |
一般社団法人 日本感染症学会
2010
|
| Online Access | Get full text |
| ISSN | 0387-5911 1884-569X |
| DOI | 10.11150/kansenshogakuzasshi.84.964 |
Cover
Loading…
| Abstract | わが国では帯状疱疹は年間4.15 人/1,000 人で，50 歳以上での発症率は，5.23～7.84 人/1,000 人であり，80歳までに，3 人に1 人が経験するありふれた感染症である．本稿では，水痘と帯状疱疹の関係，水痘ワクチンによる帯状疱疹予防の意義，水痘ワクチンによる60 歳以上の成人での帯状疱疹および帯状疱疹後神経痛予防の大規模臨床試験について考察した．また，帯状疱疹の予防という観点の研究は1980 年代から行われてきた．そして，水痘患者との接触や水痘ワクチンの接種は，既感染者の水痘帯状疱疹ウイルスに対する免疫を賦活化できることが報告されてきた．これらの一連の研究に続いて，2005 年にOxman らが，帯状疱疹予防ワクチン（ZOSTAVAX）により60 歳以上の成人の帯状疱疹と帯状疱疹後神経痛を予防できることを報告して，米国や欧州では，帯状疱疹と帯状疱疹後神経痛の標準的な予防法となったので，それを紹介し，わが国の水痘ワクチンでの帯状疱疹予防の可能性についても考察した． |
|---|---|
| AbstractList | わが国では帯状疱疹は年間4.15 人/1,000 人で，50 歳以上での発症率は，5.23～7.84 人/1,000 人であり，80歳までに，3 人に1 人が経験するありふれた感染症である．本稿では，水痘と帯状疱疹の関係，水痘ワクチンによる帯状疱疹予防の意義，水痘ワクチンによる60 歳以上の成人での帯状疱疹および帯状疱疹後神経痛予防の大規模臨床試験について考察した．また，帯状疱疹の予防という観点の研究は1980 年代から行われてきた．そして，水痘患者との接触や水痘ワクチンの接種は，既感染者の水痘帯状疱疹ウイルスに対する免疫を賦活化できることが報告されてきた．これらの一連の研究に続いて，2005 年にOxman らが，帯状疱疹予防ワクチン（ZOSTAVAX）により60 歳以上の成人の帯状疱疹と帯状疱疹後神経痛を予防できることを報告して，米国や欧州では，帯状疱疹と帯状疱疹後神経痛の標準的な予防法となったので，それを紹介し，わが国の水痘ワクチンでの帯状疱疹予防の可能性についても考察した． |
| Author | 浅野, 喜造 比嘉, 和夫 神谷, 齊 白木, 公康 中野, 貴司 |
| Author_xml | – sequence: 1 fullname: 神谷, 齊 organization: 水痘ワクチンと帯状疱疹調査研究会 – sequence: 1 fullname: 比嘉, 和夫 organization: 水痘ワクチンと帯状疱疹調査研究会 – sequence: 1 fullname: 白木, 公康 organization: 水痘ワクチンと帯状疱疹調査研究会 – sequence: 1 fullname: 中野, 貴司 organization: 水痘ワクチンと帯状疱疹調査研究会 – sequence: 1 fullname: 浅野, 喜造 organization: 水痘ワクチンと帯状疱疹調査研究会 |
| BookMark | eNptj79Lw0AcxQ-pYK39K5wT73K5y90oxV9QcVFwO77JXdu0NZVcHXQyuojuQQcRnATBooOo_04ssf-FLYqTy3vweLzHZxFVkkFiEFom2CWEMLzSg8SaxHYGbegdnYC1ndgVviu5P4eqRAjfYVzuV1AVUxE4TBKygOrWxiHGWPrYY14VOeO3UXn5WubPZf5eZA9FdltkT58fF5PrlyJ7nOT3RXZTnF19nZ6PR3dLaL4FfWvqv15De-tru41Np7mzsdVYbTpdIinMbkOpBXgi4JFshSZiXAQUAmZY5HOtPaAQChPwaYZJS4fUCBkZbTQEWlJaQ9s_u107hLZRh2l8AOmxgnQYR32j_iFXwld8JlP8v17UgVR1gX4DG8VuMQ |
| ContentType | Journal Article |
| Copyright | 2010 社団法人 日本感染症学会 |
| Copyright_xml | – notice: 2010 社団法人 日本感染症学会 |
| DOI | 10.11150/kansenshogakuzasshi.84.964 |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 1884-569X |
| EndPage | 701 |
| ExternalDocumentID | article_kansenshogakuzasshi_84_6_84_964_article_char_ja |
| GroupedDBID | ALMA_UNASSIGNED_HOLDINGS JSF KQ8 OK1 RJT SJN |
| ID | FETCH-LOGICAL-j193a-569b9d8a2876c9fbec56873a75e5c46dd2a3ab8e763a701fdb3e89cededa7d933 |
| ISSN | 0387-5911 |
| IngestDate | Wed Sep 03 06:30:00 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 6 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j193a-569b9d8a2876c9fbec56873a75e5c46dd2a3ab8e763a701fdb3e89cededa7d933 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/kansenshogakuzasshi/84/6/84_964/_article/-char/ja |
| PageCount | -262 |
| ParticipantIDs | jstage_primary_article_kansenshogakuzasshi_84_6_84_964_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 2010 |
| PublicationDateYYYYMMDD | 2010-01-01 |
| PublicationDate_xml | – year: 2010 text: 2010 |
| PublicationDecade | 2010 |
| PublicationTitle | 感染症学雑誌 |
| PublicationTitleAlternate | 感染症誌 |
| PublicationYear | 2010 |
| Publisher | 一般社団法人 日本感染症学会 |
| Publisher_xml | – name: 一般社団法人 日本感染症学会 |
| References | 3 Toyama N, Shiraki K, Members of the Society of Miyazaki Prefecture Dermatologists：Epidemiology of herpes zoster and its relationship to varicella in Japan：A 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture. J Med Virol 2009；81：2053―8. 20 Takahashi M, Okada S, Miyagawa H, Amo K,Yoshikawa K, Asada H, et al.：Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay. Vaccine 2003；21：3845―53. 17 Berger R, Luescher D, Just M：Enhancement of varicella-zoster-specific immune responses in the elderly by boosting with varicella vaccine. J Infect Dis 1984；149：647. 26 Huff JC, Bean B, Balfour HH, Laskin OL, Connor JD, Corey L, et al.：Therapy of herpes zoster with oral acyclovir. Am J Med 1988；85：84―9. 15 Baba K, Tsuda N, Yabuuchi H, Konishi S, Fujinami A, Tsujino G, et al.：Prevention of varicella in urgent cases by passive transfer of vaccine-induced immunity. Biken J 1980；23：89―94. 18 Levin MJ, Barber D, Goldblatt E, Jones M, LaFleur B, Chan C, et al.：Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older : duration of booster effect. J Infect Dis 1998；178 Suppl 1：S109―112. 24 Kamiya H, Kato T, Isaji M, Torigoe S, Oitani K,Ito M, et al.：Immunization of acute leukemic children with a live varicella vaccine (Oka strain). Biken J 1984；27：99―102. 16 Duchateau J, Vrijens R, Nicaise J, DʼHondt E,Bogearts H, Andre FE：Stimulation of specific immune response to varicella antigens in the elderly with varicella vaccine. Postgrad Med J 1985；61 Suppl 4：147―50. 8 Ljungman P, Lonnqvist B, Gahrton G, Ringden O, Sundqvist VA, Wahren B：Clinical and sub clinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis 1986；153：840―7. 4 Donahue JG, Choo PW, Manson JE, Platt R：The incidence of herpes zoster. Arch Intern Med 1995；155：1605―9. 23 450―3. Hardy I, Gershon AA, Steinberg SP, LaRussa P：The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N Engl J Med 1991；325：1545―50. 9 Arvin A：Aging, immunity, and the varicellazoster virus. N Engl J Med 2005；352：2266―7. 25 Sawtell NM, Thompson RL, Stanberry LR,Bernstein DI：Early intervention with high dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo. J Infect Dis 2001；184：964―71. 14 Yih WK, Brooks DR, Lett SM, Jumaan AO,Zhang Z, Clements KM, et al.：The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health 2005；5：68. 21 Kamiya H, Ihara T, Hattori A, Iwasa T, Sakurai M, Izawa T, et al.：Diagnostic skin test reactions with varicella virus antigen and clinical application of the test. J Infect Dis 1977；136：784―8. 22 Gershon AA, LaRussa P, Steinberg S, Mervish N, Lo SH, Meier P：The protective effect of immunologic boosting against zoster : an analysis in leukemic children who were vaccinated against chickenpox. J Infect Dis 1996；173：450―3. 19 Levin MJ, Murray M, Rotbart HA, Zerbe GO,White CJ, Hayward AR：Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis 1992；166：253―9. 12 Hope-Simpson RE：The nature of herpes zoster : a long-term study and a new hypothesis. Proc R Soc Med 1965；58：9―20. 1 Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al.：A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005；352：2271―84. 2 Harpaz R, Ortega-Sanchez IR, Seward JF : Prevention of herpes zoster：recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008；57：1―30；quiz CE32―34. 5 Heymann AD, Chodick G, Karpati T, Kamer L,Kremer E, Green MS, et al.：Diabetesasarisk factor for herpes zoster infection：results of a population-based study in Israel. Infection 2008；36：226―30. 7 Buchbinder SP, Katz MH, Hessol NA, Liu JY,OʼMalley PM, Underwood R, et al.：Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992；166：1153―6. 11 Kawaguchi T, Spencer DB, Mochizuki M：Therapy for acute retinal necrosis. Semin Oph thalmol 2008；23：285―90. 28 神谷齊，浅野喜造，尾崎隆男，馬場宏一，熊谷卓司，永井崇雄，白木公康：水痘ワクチンの力価と流通時のワクチン力価の安定性．未発表 13 Thomas SL, Wheeler JG, Hall AJ：Contacts with varicella or with children and protection against herpes zoster in adults : a case-control study. Lancet 2002；360：678―82. 6 Strangfeld A, Listing J, Herzer P, Liebhaber A,Rockwitz K, Richter C, et al.：Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009；301：737―44. 10 Morgan M, Moffat M, Ritchie L, Collacott I,Brown T：Is Bellʼs palsy a reactivation of varicella zoster virus? J Infect 1995；30：29― 36. 27 Prevention of varicella：Recommendations of the Advisory Committee on Immunization Practices (ACIP)：Centers for Disease Control and Prevention. MMWR Recomm Rep 1996；45：1―36. |
| References_xml | – reference: 12 Hope-Simpson RE：The nature of herpes zoster : a long-term study and a new hypothesis. Proc R Soc Med 1965；58：9―20. – reference: 18 Levin MJ, Barber D, Goldblatt E, Jones M, LaFleur B, Chan C, et al.：Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older : duration of booster effect. J Infect Dis 1998；178 Suppl 1：S109―112. – reference: 17 Berger R, Luescher D, Just M：Enhancement of varicella-zoster-specific immune responses in the elderly by boosting with varicella vaccine. J Infect Dis 1984；149：647. – reference: 7 Buchbinder SP, Katz MH, Hessol NA, Liu JY,OʼMalley PM, Underwood R, et al.：Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992；166：1153―6. – reference: 25 Sawtell NM, Thompson RL, Stanberry LR,Bernstein DI：Early intervention with high dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo. J Infect Dis 2001；184：964―71. – reference: 27 Prevention of varicella：Recommendations of the Advisory Committee on Immunization Practices (ACIP)：Centers for Disease Control and Prevention. MMWR Recomm Rep 1996；45：1―36. – reference: 10 Morgan M, Moffat M, Ritchie L, Collacott I,Brown T：Is Bellʼs palsy a reactivation of varicella zoster virus? J Infect 1995；30：29― 36. – reference: 21 Kamiya H, Ihara T, Hattori A, Iwasa T, Sakurai M, Izawa T, et al.：Diagnostic skin test reactions with varicella virus antigen and clinical application of the test. J Infect Dis 1977；136：784―8. – reference: 8 Ljungman P, Lonnqvist B, Gahrton G, Ringden O, Sundqvist VA, Wahren B：Clinical and sub clinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis 1986；153：840―7. – reference: 9 Arvin A：Aging, immunity, and the varicellazoster virus. N Engl J Med 2005；352：2266―7. – reference: 23 450―3. Hardy I, Gershon AA, Steinberg SP, LaRussa P：The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N Engl J Med 1991；325：1545―50. – reference: 5 Heymann AD, Chodick G, Karpati T, Kamer L,Kremer E, Green MS, et al.：Diabetesasarisk factor for herpes zoster infection：results of a population-based study in Israel. Infection 2008；36：226―30. – reference: 16 Duchateau J, Vrijens R, Nicaise J, DʼHondt E,Bogearts H, Andre FE：Stimulation of specific immune response to varicella antigens in the elderly with varicella vaccine. Postgrad Med J 1985；61 Suppl 4：147―50. – reference: 24 Kamiya H, Kato T, Isaji M, Torigoe S, Oitani K,Ito M, et al.：Immunization of acute leukemic children with a live varicella vaccine (Oka strain). Biken J 1984；27：99―102. – reference: 22 Gershon AA, LaRussa P, Steinberg S, Mervish N, Lo SH, Meier P：The protective effect of immunologic boosting against zoster : an analysis in leukemic children who were vaccinated against chickenpox. J Infect Dis 1996；173：450―3. – reference: 28 神谷齊，浅野喜造，尾崎隆男，馬場宏一，熊谷卓司，永井崇雄，白木公康：水痘ワクチンの力価と流通時のワクチン力価の安定性．未発表 – reference: 14 Yih WK, Brooks DR, Lett SM, Jumaan AO,Zhang Z, Clements KM, et al.：The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health 2005；5：68. – reference: 20 Takahashi M, Okada S, Miyagawa H, Amo K,Yoshikawa K, Asada H, et al.：Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay. Vaccine 2003；21：3845―53. – reference: 13 Thomas SL, Wheeler JG, Hall AJ：Contacts with varicella or with children and protection against herpes zoster in adults : a case-control study. Lancet 2002；360：678―82. – reference: 2 Harpaz R, Ortega-Sanchez IR, Seward JF : Prevention of herpes zoster：recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008；57：1―30；quiz CE32―34. – reference: 4 Donahue JG, Choo PW, Manson JE, Platt R：The incidence of herpes zoster. Arch Intern Med 1995；155：1605―9. – reference: 11 Kawaguchi T, Spencer DB, Mochizuki M：Therapy for acute retinal necrosis. Semin Oph thalmol 2008；23：285―90. – reference: 15 Baba K, Tsuda N, Yabuuchi H, Konishi S, Fujinami A, Tsujino G, et al.：Prevention of varicella in urgent cases by passive transfer of vaccine-induced immunity. Biken J 1980；23：89―94. – reference: 19 Levin MJ, Murray M, Rotbart HA, Zerbe GO,White CJ, Hayward AR：Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis 1992；166：253―9. – reference: 26 Huff JC, Bean B, Balfour HH, Laskin OL, Connor JD, Corey L, et al.：Therapy of herpes zoster with oral acyclovir. Am J Med 1988；85：84―9. – reference: 1 Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al.：A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005；352：2271―84. – reference: 3 Toyama N, Shiraki K, Members of the Society of Miyazaki Prefecture Dermatologists：Epidemiology of herpes zoster and its relationship to varicella in Japan：A 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture. J Med Virol 2009；81：2053―8. – reference: 6 Strangfeld A, Listing J, Herzer P, Liebhaber A,Rockwitz K, Richter C, et al.：Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009；301：737―44. |
| SSID | ssib000940252 ssib008799519 ssib058493432 ssib000959785 ssib020873179 ssib028667260 ssib002821772 ssj0000816464 ssib003038878 ssib002670505 ssib050995440 |
| Score | 1.8359778 |
| Snippet | わが国では帯状疱疹は年間4.15 人/1,000 人で，50 歳以上での発症率は，5.23～7.84 人/1,000 人であり，80歳までに，3 人に1 人が経験するありふれた感染症である．本稿では，水痘と帯状疱疹の関係，水痘ワクチンによる帯状疱疹予防の意義，水痘ワクチンによる60... |
| SourceID | jstage |
| SourceType | Publisher |
| StartPage | 964 |
| Title | 帯状疱疹とその予防に関する考察 |
| URI | https://www.jstage.jst.go.jp/article/kansenshogakuzasshi/84/6/84_964/_article/-char/ja |
| Volume | 84 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | 感染症学雑誌, 2010/09/20, Vol.84(6), pp.964-701 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR1NaxUxcKkVxIsoKlo_KGhOstXdfB837-2jKApCC70t-5G1vkIr2l568ulF9F70IIInQbDoQax_51lq_4Uz2d23W6hQi5eQl0wmk5m8ZCY7mXjezTBMU5VS5mcCg2qXmfBVpks_t0GmCx7YUuB95_sPxPwiu7vEl6ZO7HS8ljbWs7l889B7JceRKpSBXPGW7D9IdoIUCiAP8oUUJAzpkWRMYk6MItGAxJKoiBiBGS2ICZqMJjEFbZFEqs7oflMSk5gRExEFVZpoRUzYVBlXIkjUlOgKT0gUVCl0j1AUe4eu9QHPQBILohgUYgZSTR0lQJ508H0SCYfcEB0gqggImJzUImzEiY6xxtwhRuIUQHjThwG2YML1zBAlEK50BQY_gMKe64jBKLpotcOBRPWQGTW8AkgHD3wwsoVnjq997BkIV3EF71hkXK9qABDdI5PabRand90cmISsUq4HiRSZ2NFoSESREkOJ5rUQTHTLEefGX1PZOxozoX2P6KizpGMkY67r7cVWW45SzOfCPSg82ZOqZ_Pq_153g9FVzPdaV5HVQdAh2yBHx9GVFL9PPFtee5SubGyCMbb8eE6xuQmOA3HG61mcHNIoUSwRmEDLpIHDW4HJEEyTk6GUAXrT3nvY0ew1A226ozlrsFw7YZJCIfENxa7lH0jZjWRHYftr8SkMXNhGHgyhgAbtB-ZQwVITtpY-qMGaszaMEajZenKF2ilpCgPrVcHlapmc8m40vLv9d86BpjoEu63x-XRq6MJZ70xtP85GFXvOeVPD9Lzn7_7Y3nv9fW_r697Wznj0aTx6Px59-fXz1f7bb-PR5_2tj-PRu_GLN7-fv9zd_nDBWxzEC715v34HxR-CeZXi5IB1U6UhaC65LmHV5QKGn0puec5EUYQpTTNlQVVIYUaURUat0rktbJHKQlN60ZteXVu1l7xZbjMMeZmHlFNWWpmWUtmCZZqK3OpCX_YG1eiSJ1Wwm-SY02LmfyG64p2uHHbw1POqN73-dMNeAztgPbvuZtwfqljW5A |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E5%B8%AF%E7%8A%B6%E7%96%B1%E7%96%B9%E3%81%A8%E3%81%9D%E3%81%AE%E4%BA%88%E9%98%B2%E3%81%AB%E9%96%A2%E3%81%99%E3%82%8B%E8%80%83%E5%AF%9F&rft.jtitle=%E6%84%9F%E6%9F%93%E7%97%87%E5%AD%A6%E9%9B%91%E8%AA%8C&rft.au=%E7%A5%9E%E8%B0%B7%2C+%E9%BD%8A&rft.au=%E6%AF%94%E5%98%89%2C+%E5%92%8C%E5%A4%AB&rft.au=%E7%99%BD%E6%9C%A8%2C+%E5%85%AC%E5%BA%B7&rft.au=%E4%B8%AD%E9%87%8E%2C+%E8%B2%B4%E5%8F%B8&rft.date=2010&rft.pub=%E4%B8%80%E8%88%AC%E7%A4%BE%E5%9B%A3%E6%B3%95%E4%BA%BA+%E6%97%A5%E6%9C%AC%E6%84%9F%E6%9F%93%E7%97%87%E5%AD%A6%E4%BC%9A&rft.issn=0387-5911&rft.eissn=1884-569X&rft.volume=84&rft.issue=6&rft.spage=964&rft.epage=701&rft_id=info:doi/10.11150%2Fkansenshogakuzasshi.84.964&rft.externalDocID=article_kansenshogakuzasshi_84_6_84_964_article_char_ja |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0387-5911&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0387-5911&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0387-5911&client=summon |